A Clinical Assessment of the Therapeutic Effects of Ashwagandha Root Extract on Cognitive Performance, Sleep, and Fatigue in Children Aged 6–12 Years

Why It Matters

The results offer a potential non‑pharmacologic option for improving cognitive function and sleep in children, addressing safety concerns associated with stimulant medications.

Key Takeaways

• 85 children randomized; 73 completed trial.
• Ashwagandha improved processing speed (p=0.04).
• Memory and executive tasks showed moderate effect sizes.
• Sleep Disturbance Scale scores improved significantly.
• No serious adverse events reported.

Pulse Analysis

The pediatric market has long sought alternatives to stimulant drugs for attention and memory challenges, especially given the side‑effect profile of traditional medications. This trial introduces a botanical candidate—standardized Ashwagandha root extract—delivered in a child‑friendly gummy format. By demonstrating measurable improvements in processing speed, delayed recall, and executive function tasks, the study adds to a growing body of evidence that adaptogens can modulate neurocognitive pathways even in developing brains. The observed effect sizes (Cohen’s d around 0.6‑0.75) are comparable to modest gains reported for low‑dose cognitive enhancers, suggesting practical relevance for parents and educators seeking safe, over‑the‑counter options.

Mechanistically, withanolides in Ashwagandha are known to influence GABAergic activity, reduce cortisol, and protect against oxidative stress, all of which can support neural plasticity and sleep regulation. The trial’s secondary outcome—significant reduction in Sleep Disturbance Scale scores—highlights a dual benefit, as better sleep is tightly linked to memory consolidation and learning in children. This synergy may explain part of the cognitive gains observed, positioning Ashwagandha as a holistic supplement rather than a single‑target drug. For clinicians, the absence of serious adverse events and the mild nature of reported side effects reinforce its safety profile, a critical consideration for long‑term pediatric use.

Looking ahead, larger, intention‑to‑treat studies with diverse populations and longer follow‑up periods are needed to confirm durability of benefits and to explore dose‑response relationships. Objective neuroimaging or electrophysiological markers could clarify the underlying neurobiological changes. If future research validates these early findings, Ashwagandha could become a mainstream adjunct in pediatric wellness programs, influencing supplement retail strategies and prompting insurers to consider coverage for evidence‑based botanical interventions.